Important functional differences exist between primitive CD34
Introduction
Human hematopoiesis occurs at three major sites during embryonic and fetal development. It starts in the third week of gestation in the blood islands of the yolk sac, and then migrates during the sixth week to the FL and spleen. Subsequently, at week 20, hematopoiesis homes to the bone marrow which finally takes over the whole blood cell production. [1] [2] [3] [4] Recently, Tavian et al 5 identified a CD34-expressing hematopoietic cell compartment associated with the ventral endothelium of the aorta in 5-week-old human embryos. Moreover, additional sites of hematopoiesis (eg dorsal aorta, cardinal veins and proximal umbilical and vitelline arteries) were found in day 8 to day 10 mouse embryos, 6 while primitive hematopoietic stem cells also were found in adult mouse liver. 7, 8 At least part of human hematopoietic stem cells have been shown by in vivo experiments (myelopoietic and lymphopoietic capacity) and in vitro experiments (engraftment of long-term sustainable human hematopoiesis in fetal sheep and in immunodeficient mice) to be contained within the CD34 ++ CD38 − fraction. [9] [10] [11] [12] However, when compared to ABM CD34
++

CD38
− cells, phenotypically identical cells derived from ontogenically earlier sources such as cord blood (CB) and FL show important intrinsic functional differences. Indeed, the maximal proliferative capacity of CD34 ++ CD38
− cells is inversely correlated with their ontogenic age. 13, 14 Moreover, we have recently shown that the growth factor requirements of CD34
++
CD38
− cells derived from FL and CB are much less stringent than those for their ABM counterparts. 15 In order to better understand these differences between FLand ABM-derived CD34
++
CD38
− cells, we investigated whether factors, known to modulate the growth of hematopoietic progenitors, have different effects on ABM as opposed to FL cells. It has been shown previously by Hatzfeld et al 16 that primitive ABM multipotent progenitor cells produce TGF-␤ in an endogenous fashion, keeping these cells in a quiescent state. Therefore, we wanted to compare the effects of exogenously added TGF-␤ on the cell proliferation and CFU generation of primitive FL and ABM cells. We furthermore used anti-TGF-␤ antibodies to study the effects of blocking endogenously produced TGF-␤ on these cells populations. Third, we investigated whether these blocking anti-TGF-␤ antibodies might reduce the growth factor requirements of the ABM cell population in order to proliferate and generate secondary colonies.
The results from these experiments support the model of the group of Hatzfeld et al [16] [17] [18] that TGF-␤ plays a central role in controlling the quiescence of hematopoietic primitive cells, and led us to extend their results with the fact that the TGF-␤ system, and more specifically the developmental different responsiveness to TGF-␤, is an important determinant of the intrinsic functional characteristics of human hematopoietic stem cells derived from ontogenically different sources.
Materials and methods
Fetal liver and adult bone marrow cell purification and culture
Human FL (18-22 weeks gestation) and ABM cells (sternal puncture from hematologically normal patients undergoing cardiac surgery) were obtained, stored, purified and cultured as described before. 15 In brief, cells were labeled with 43A1 supernatant as a source of anti-CD34 antibodies (IgG3, kindly donated by Dr HJ Bü hring, University of Tü bingen, Germany), 19 stained with fluorescein isothiocyanate-conjugated rabbit anti-mouse immunoglobulins (RAM-FITC) and with phycoerythrin (PE)-conjugated anti-CD38. Cells were sorted on a FACStar Plus Cells Sorter (Becton Dickinson, Erembodegem, Belgium). Cells with a low to medium forward scatter and a low side scatter, a highly positive green (CD34) flu-orescence, and an orange (CD38) fluorescence signal lower than the mean fluorescence of cells labeled with an irrelevant isotype-matched control antibody +2 standard deviations were retained as CD34
++ CD38 − cells. Purities were always Ͼ95%. Sorting regions are depicted in Figure 1 . Cells (200 per well) were cultured in pre-colony-forming unit (pre-CFU) assays. In this assay, liquid cultures were performed in duplicate in 96-well flat-bottomed plates in IMDM (GIBCO, Paisley, UK) containing 10% fetal calf serum (FCS), 1% bovine serum albumin (BSA) and different combinations of recombinant human (rhu) interleukin (IL)-1, IL-6, IL-3, rhu stem cell factor (SCF) and varying concentrations of TGF-␤ and anti-TGF-␤. ABM and FL cells were cultured at 37°C in 7.5% O 2 and 5% CO 2 in a fully humidified incubator for 7 and 14 days, after which the cells were counted, harvested and plated in duplicate in secondary methylcellulose cultures (0.9%) supplemented with 20% FCS, 1% BSA, 10% conditioned medium of the 5637 bladder carcinoma cell line (containing G-CSF and GM-CSF), IL-6, IL-3, erythropoietin (epo) and 2-mercaptoethanol. These cultures were microscopically scored for colony formation after 14 days of culture at 37°C in 7.5% O 2 and 5% CO 2 in a fully humidified incubator.
All samples were obtained after informed consent according to the guidelines of the Medical Ethics Committees of the University Hospitals of Ghent and Antwerp.
Cytokines and monoclonal antibodies
RAM-FITC [F(abЈ) 2 fragments] was purchased from Dako (Glostrup, Denmark). CD38-PE as well as isotype-matched control antibodies were purchased from Becton Dickinson (Erembodegem, Belgium), mouse gammaglobulins from Jackson Immuno Research Laboratories (West Baltimore Pike, PA, USA). IL-1 (specific activity (sa) Ͼ5 × 10 7 U/mg), rhuIL-6 (sa Ͼ1 × 10 8 U/mg), and SCF (sa Ͼ1 × 10 5 U/mg) were obtained from Boehringer Mannheim (Penzberg, Germany), epo (sa ෂ1 × 10 5 U/mg) from Cilag (Brussels, Belgium). rhuIL-3 (biological activity 14 × 10 3 U/ml) was a kind gift of Dr SC Clark (Genetics Institute, Cambridge, MA, USA). Ultrapure natural human TGF-␤ (sa ෂ1 × 10 6 U/mg), monoclonal mouse anti-TGF-␤ 1 , ␤ 2 , ␤ 3 and monoclonal mouse anti-human IL-2 (irrelevant control antibody) were purchased from Genzyme (Cambridge, MA, USA). 
TGF-␤ measurements
TGF-␤ levels in (1) culture medium containing FCS and BSA and in (2) the supernatant of 3000-5000 FL and ABM CD34
++
CD38
− cells, cultured during 36-48 h in serum-free medium (X-VIVO 15; Biowhittaker, Walkersville, USA), containing 100 ng/ml IL-1, 200 U/ml IL-6, 30 U/ml IL-3 and 100 ng/ml SCF were measured using a sensitive (Ͼ25 pg/ml) immunoenzymatic method (TGF-␤ 1 Emax ™ ; Promega, Madison, WI, USA), performed according to the instructions of the manufacturer.
Statistics
Intra-FL or intra-ABM comparisons were validated using the Student's t-test for paired samples. All other comparisons were based on the unpaired t-test. Results are expressed as mean ± standard error of the mean (s.e.m.).
Results
We investigated the effects of TGF-␤ and blocking anti-TGF-␤ antibodies in a pre-CFU assay. In this assay, CD34
++ CD38
− cells from FL and ABM are cultured in a primary liquid culture, containing an optimal stimulatory combination of early acting cytokines (IL-1 + IL-3 + IL-6 + SCF), after which the cells are counted and plated in semisolid cultures. In this way, the generation of progenitor cells from their precursors, undetectable in direct semisolid assays, can be quantitated so that the effects of TGF-␤ and anti-TGF-␤ on the initial phase of the proliferation and differentiation of very primitive progenitor cells are assessed.
10,15
In a first set of experiments, we evaluated the maximal cell proliferation and CFU generation at two time points: day 7 and day 14. As shown in Figure 2a and b we found that both at day 7 and day 14 CD34
++
CD38
− FL cells had a significantly higher proliferative capacity and secondary CFU output than their ABM counterparts. Both ABM and FL progenitors showed a multilineage content as was evidenced by the output of myeloid (macrophage, granulocyte and granulocytemacrophage), erythroid and mixed erythroid-myeloid colonies, although no significant differences in colony type or col- ony size were noted between both cell fractions, which was in agreement with our previous results. 15 These experiments also demonstrated that the highest rate of proliferation and generation of secondary CFU of FL cells was situated in the first 7 days of the culture period, whereas ABM cells needed another 7 days to reach their highest proliferation rate.
In a next set of experiments we investigated the effects of neutralizing anti-TGF-␤ antibodies on FL and ABM CD34
++ CD38 − cells. It has been shown previously by Hatzfeld et al 16 that primitive ABM multipotent progenitor cells produce TGF-␤ in an endogenous fashion, keeping these cells in a quiescent state. Addition of anti-TGF-␤, but not of an irrelevant control antibody (anti-IL-2, not shown), to IL-1 + IL-3 + IL-6 + SCF-stimulated cells resulted in a very potent stimulation of the proliferation and of the secondary CFU output of ABM cells, especially at day 14: 3.3 ± 0.2-fold (P Ͻ 0.001) cell number expansion and 5.2 ± 1.8-fold (P = 0.03) CFU expansion at day 7, and 22.5 ± 4.5-fold (P Ͻ 0.001) cell number expansion and 21.6 ± 4.5-fold (P = 0.002) CFU expansion at day 14 ( Figure 3a and b) . This was in strong contrast with the impact of anti-TGF-␤ on FL CD34
++ CD38 − cells, where a far less pronounced effect was noted at both time-points: 1.9 ± 0.3-fold (P Ͻ 0.005) cell number expansion and 2.5 ± 0.7-fold (P = 0.03) CFU expansion at day 7, and 1.4 ± 0.1-fold (P = 0.047) cell number expansion and 0.7 ± 0.2-fold (P = NS) CFU expansion, respectively, at day 14 (Figure 3a and b) .
This means that when FL and ABM progenitors are compared, the difference in maximal proliferative capacity between these cell fractions is significantly reduced from 174.0-fold (no anti-TGF-␤) to 74.5-fold (+ anti-TGF-␤) at day 7 (reduction factor: 2.3), and from 182.9-fold to 15.5-fold at day 14 (reduction factor: 11.9). This is paralleled by an equally strong reduction in the difference in secondary CFU generation between FL and ABM cells: from 268.8-fold to 109.7-fold at day 7 (reduction factor: 2.5), and from 47.8-fold to 4.3-fold at day 14 (reduction factor: 11.1). Thus, at the end of the 14-day culture period, the cell proliferation and especially the production of secondary CFU of FL and ABM cells approached each other when anti-TGF-␤ was present in the cultures.
In ABM, anti-TGF-␤ induced the highest increase in cell number and secondary CFU generation during the second week of culture (Figure 3a and b) . This may indicate either that anti-TGF-␤ especially induces cycling of very primitive progenitors with a higher proliferation potential, and therefore a large progeny, or that it supports especially the proliferation at the level of more mature progenitors. We therefore added anti-TGF-␤ during the first 36 h of the primary liquid culture,
Figure 3
Effects of anti-TGF-␤ on the primary liquid culture total cell number (a) and subsequent secondary CFU output (b) of CD34
++
CD38
− cells derived from ABM and FL after 7 days (í) and 14 days () liquid culture supported by IL-1 + IL-3 + IL-6 + SCF. Results (mean ± s.e.m.) are expressed as % vs control without anti-TGF-␤. (n = number of independent individual experiments).
after which the cells were washed and cultured for another 12 days without anti-TGF-␤, and compared this with a 14 day culture period in the presence of anti-TGF-␤. As shown in Figure 4 , no significant difference in cell number was seen between both conditions, indicating that anti-TGF-␤ is only essential during the first 36 h of the primary culture, confirming the results of Sansilvestri et al 20 and of Hatzfeld et al.
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These data clearly show that the effect of anti-TGF-␤ is mainly situated at the level of the initial cell cycles of very primitive progenitor cells with a high proliferation potential. Addition of exogenous TGF-␤ to the pre-CFU cultures resulted in a strong inhibition of cell proliferation and of secondary CFU generation from both ABM and FL cells (Figure  5a and b) . However, at the highest TGF-␤ concentration used, FL cells were significantly less sensitive to the overall inhibitory effects of TGF-␤ than ABM cells (day 7: −53.8 ± 16.7% vs −77.4 ± 4.5% (P = not significant (NS) for FL and ABM cell proliferation, respectively, and −52.4 ± 10.5% vs −82.7 ± 6.3% (P = 0.026) for FL and ABM CFU generation, respectively; day 14: −70.9 ± 8.0% vs −94.0 ± 0.9% (P Ͻ 0.001) for FL and ABM cell proliferation, respectively, and −53.3 ± 17.1% vs −82.3 ± 4.9% (P = 0.04) for FL and ABM CFU generation, respectively).
The fact that FCS and BSA used in our cultures contained on average 0.13 ng/ml TGF-␤ (final concentration in the culture medium), a concentration at which exogenously added TGF-␤ has little or no effect ( Figure 5 ), indicates that these effects of anti-TGF-␤ are mainly mediated through the blockade of autocrinely and/or paracrinely produced TGF-␤, but not of TGF-␤ present in the culture medium. We furthermore measured TGF-␤ production by 3000-5000 ABM or FL CD34
++
CD38
− cells after 24-48 h culture in serum-free medium. Using a highly sensitive ELISA technique, the levels of TGF-␤ were near the detection limit (not shown), but no difference in TGF-␤ production level between FL and ABM could be demonstrated.
As we have shown previously, an important functional difference between FL and ABM cells are the less stringent growth factor requirements of FL CD34 ++ CD38 − cells when compared to their ABM counterparts. 15 Indeed, whereas optimal cell proliferation of ABM cells requires the presence of a 4-cytokine cocktail (IL-1 + IL-3 + IL-6 + SCF), the combination of IL-3 + SCF is already sufficient to obtain maximal cell proliferation of FL cells. 10, 15 We hypothesized that blocking the effects of endogenous TGF-␤ by adding anti-TGF-␤ antibodies to the stimulatory cytokine cocktail might reduce the cytokine requirements of the ABM cell population. To test this hypothesis, we limited the combination of early acting cytokines in the pre-CFU assay from IL-1 + IL-3 + IL-6 + SCF to IL-3 + SCF ± anti-TGF-␤ (Table 1) . Interestingly, already at day 7 the use of the 2-cytokine cocktail reduced the ABM cell proliferation with 50.9 ± 6.0% (P Ͻ 0.001) vs control (ie the 4-cytokine cocktail). This reduction was completely abrogated after the addition of anti-TGF-␤ to the two cytokines, which even resulted in a significant stimulation of cell proliferation of 160.9 ± 11.9% (P Ͻ 0.001) vs the 4-cytokine control, although it did not reach the cell proliferation seen with the combination of the 4-cytokine cocktail + anti-TGF-␤. At the level of CFU generation, anti-TGF-␤ again abrogated the reduction noted after incubation with two cytokines (from −86.8 ± 6.1% (P Ͻ 0.001) to 102.5 ± 30.0% vs control (P = NS)). However, as could be anticipated for FL CD34
− cells, reducing the 4-cytokine cocktail to the combination of Results are expressed as mean percentage ± s.e.m. of control (ie the 4-cytokine cocktail containing IL-1/IL-3/IL-6/SCF).
a Significantly different vs control (P Ͻ 0.05). CFU, secondary CFU output. ABM: n = 9; FL: n = 2.
IL-3 + SCF did not result in a significant alteration of cell proliferation (103.6 ± 33.9% (P = NS) vs control), thus confirming our previous results. 15 Addition of anti-TGF-␤ to IL-3 + SCF resulted in a minor, albeit not significant, increase in FL cell proliferation (124.4 ± 43.5% (P = NS) vs control). Again for the secondary CFU output, no significant changes were seen when reducing the cytokine cocktail, with or without the addition of anti-TGF-␤.
Discussion
In this report we show for the first time that the TGF-␤ system is an important determinant of the intrinsic functional characteristics of primitive hematopoietic progenitor cells derived from ontogenically different sources.
It is important to note that the developmentally regulated responsiveness to TGF-␤ is more dramatic than it appears from experiments where the sensitivity of FL and ABM cells to the effects of exogenously added TGF-␤ are compared. Since exogenous TGF-␤ reduces the proliferation of ABM 17-fold (−94.0%) over baseline ( Figure 5) , and since neutralization of endogenously produced TGF-␤ increases proliferation 22.5-fold over baseline (Figure 3) , TGF-␤ actually reduces the maximal proliferation of ABM CD34 ++ CD38 − cells by a near 400-fold (17 × 22.5). In FL on the other hand, anti-TGF-␤ results in a 1.4-fold increase (Figure 3) , and exogenously added TGF-␤ in a 3.4-fold (−70.9%) decrease in proliferation ( Figure 5 ), so that the maximal effect of TGF-␤ is at best a five-fold (1.4 × 3.4) reduction in proliferative capacity. This implies that the sensitivity of CD34 ++ CD38 − cells from ABM to TGF-␤ is at least 80-to 100-fold higher compared to their FL counterparts, indicating a developmentally regulated responsiveness to TGF-␤. It should be kept in mind that the differences in TGF-␤ responsiveness between FL and ABM can only be defined as being a global effect, since clonal heterogeneity in the purified CD34 ++ CD38 − cells was not excluded. Therefore clonal analysis of the TGF-␤ effect is currently under investigation.
This increase in the response to TGF-␤ with ontogenic age may possibly explain two major functional differences that exist between FL and ABM multipotent progenitor cells, ie the lower proliferative capacity and the higher growth factor requirements of adult cells when compared to fetal liver cells. First, we show in our study that blocking the TGF-␤ effects by using monoclonal anti-TGF-␤ antibodies results in a spectacular reduction of the difference in maximal proliferative capacity and secondary CFU generation between ABM and FL cells, indicating that the 80-to 100-fold difference in TGF-␤ sensitivity between ABM and FL CD34
++
CD38
− cells might account for the major part of the more than 100-fold difference in maximal proliferative capacity between FL and ABM CD34 ++ CD38 − cells reported here and previously. 14, 15 Second, our study demonstrates that the elimination of TGF-␤ activity on primitive ABM cells results in a reduced growth factor requirement, comparable to the requirements of FL cells. It has previously been shown that TGF-␤ is an important regulator of the responsiveness of human hematopoietic stem/progenitor cells to several cytokines such as SCF, IL-3, IL-1, and Flt3 ligand. The inhibitory action of TGF-␤ on cell growth is probably associated with the fact that TGF-␤ has direct effects on cell surface expression of some cytokine receptors, which is already been demonstrated by the down-modulation of the receptors for IL-1, IL-3, M-CSF and SCF on hematopoietic cells, depriving them of the ability to respond to these cytokines. [22] [23] [24] [25] [26] [27] [28] Sansilvestri et al 20 showed that two subpopulations of CD34 high cells can be distinguished: one subpopulation that expresses c-kit that can be downmodulated by exogenous TGF-␤, and another subpopulation that expresses a low level of c-kit that can be upregulated by anti-TGF-␤. Interestingly, these CD34 + Kit low cells have been reported to contain significant levels of long-term marrow-engrafting hematopoietic stem cells. 29 Recently, Fortunel et al 18 demonstrated that anti-TGF-␤ also allows the rapid expression of both the Flt3 and the Il-6 receptors in quiescent cells which can then respond to these cytokines present in the culture medium.
TGF-␤ is a ubiquitously present cytokine produced by progenitor cells, stromal cells, and many other cells and tissues, making it reasonable to accept that the functional differences between FL and ABM progenitors are regulated at the level of response to TGF-␤ rather than at the level of production of TGF-␤ be it acting autocrinely, paracrinely or even endocrinely. However, since we could not demonstrate a different TGF-␤ production level between both cell fractions, we are currently investigating whether this difference in responsiveness to TGF-␤ is regulated at the level of receptor modulation, or rather at the level of the downstream signalling pathways.
What might be the biological significance of our findings? As shown by Vaziri et al, 30 and recently confirmed by Engelhardt et al, 31 adult stem cells have significantly shortened telomeres when compared with FL cells. The shortening of telomeres with age in human stem cells indicates that stem cell populations probably cycle throughout life time, and that hematopoietic stem cells have a limited and defined replicative life span. 32 It can be anticipated that the highest level of stem cell expansion occurs during fetal and postnatal growth of the individual since it has been demonstrated that the cycling activity of stem cells in fetal and young mice is higher than in old mice, whereas the size of the stem cell pool increases with age. [33] [34] [35] [36] Based on our data in the human system, we speculate that the induction of an increased sensitivity to TGF-␤ could possibly be one of the molecular changes associated with replicative aging of stem cells. This implies that TGF-␤ responsiveness might be related with the cycling status and the pool size of stem cells. According to this hypothesis, the relative resistance to the inhibitory effects of TGF-␤ would allow the stem cell compartment to expand in young individuals, whereas in older individuals, the expanded and now quiescent stem cell pool would decrease its rate of cycling due to an increased responsiveness to TGF-␤. This would be in accordance with the working model of Fortunel et al 18 who introduced the 'high proliferative potential-quiescent cells', being primitive progenitor cells that are highly sensitive to the growth inhibitory effect of TGF-␤. It has furthermore been shown that FL stem cells in mice have a higher reconstituting potential than ABM cells, and that this reconstituting capacity of stem cells decreases upon serial transplantation. 37, 38 Therefore the responsiveness to TGF-␤ may determine the 'quality' of stem cells in terms of reconstituting capacity and developmental potential, indicating that an increased responsiveness to TGF-␤ after extensive renewal, and thus replicative senescence of stem cells, may explain the decreasing reconstituting capacity of stem cells upon serial transplantation. 38, 39 Telomeres are thought to function as a mitotic clock, and telomere shortening is thought to induce the phenotypic changes associated with cellular senescence. 32 Therefore, our data suggest that the induction of a functional inhibitory TGF-␤ loop, associated with increasing replicative age of stem cells, is paralleled by telomere shortening. The increased sensitivity of ABM CD34
++
CD38
− cells to endogenously produced TGF-␤ limits unnecessary further expansion of the stem cell compartment. This may serve as a protective mechanism against recruitment and subsequent critical telomere shortening, and therefore against genomic instability and transformation. Indeed, the TGF-␤ system is clearly emerging as an important tumor suppressor mechanism in several organ systems, and very recently, TGF-␤1 has been shown to be a new form of tumor suppressor in the liver and lung. [40] [41] [42] Taken together, our data clearly show for the first time that at least part of the physiological differences between human adult and fetal primitive hematopoietic progenitor cells can be explained by a developmentally regulated increase in the responsiveness to TGF-␤ from FL to ABM stem cells.
